Acotec Scientific Holdings Ltd. has announced that it has received registration approval from the PRC National Medical Products Administration for its Vertebral Artery Paclitaxel-coated Balloon Dilatation Catheter, AcoArt Verbena®. This device is intended for percutaneous transluminal angioplasty in symptomatic patients with significant stenosis at the origin of the vertebral artery. The approval marks a significant step in advancing treatment for vertebral artery stenosis, promising a new era of "Leave Nothing Behind" in medical procedures. The clinical trials showed that AcoArt Verbena® had a restenosis rate of 13.04% at 12 months post-procedure, significantly lower than the control group's rate of 37.31%. This approval is a key development for Acotec Scientific Holdings Ltd. as it plans to commence marketing efforts in the PRC market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.